Showing 1 - 5 results of 5 for search 'Patrick F. Smith', query time: 0.02s Refine Results
  1. 1
    Optimizing COVID‐19 Candidate Therapeutics: Thinking Without Borders

    Optimizing COVID‐19 Candidate Therapeutics: Thinking Without Borders by Craig R. Rayner, Patrick F. Smith, Kevin Hershberger, David Wesche

    Published 2020
    Connect to this object online.
    Book
    Save to List
    Saved in:
  2. 2
    An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study

    An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study by David Kallend, Jay Mason, Patrick F. Smith, Michael J. Koren, Robert Stoekenbroek, YanLing He, Peter Wijngaard

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  3. 3
    Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants

    Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants by Sibel Ucpinar, Patrick F. Smith, Li Long, Fujun Li, Hui Yan, Jyoti Wadhwa, Katherine A. Chu, Jin Shu, Philip Nunn, Mengyao Li

    Published 2023
    Connect to this object online.
    Book
    Save to List
    Saved in:
  4. 4
    A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects

    A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects by Sibel Ucpinar, Borje Darpo, Ann Neale, Philip Nunn, Jin Shu, Katherine A. Chu, Marianne Kavanagh, Hongqi Xue, Pasit Phiasivongsa, Dolca Thomas, Patrick F. Smith

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  5. 5
    Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)

    Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168) by Timothy D. Owens, Patrick F. Smith, Andrew Redfern, Yan Xing, Jin Shu, Dane E. Karr, Sonja Hartmann, Michelle R. Francesco, Claire L. Langrish, Philip A. Nunn, Steven G. Gourlay

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:

Search Tools: